Glenmark Pharma gets nod to raise up to $300 million

01 Jan 2015 Evaluate

Glenmark Pharmaceuticals has received shareholders’ approval to raise up to $300 million (around Rs 1,890 crore) through issue of securities. The proposal to issue securities not exceeding $300 million was approved by with 96.07% votes in favour through postal ballot.

The company’s shareholders also approved hiking the shareholding limit for foreign institutional investors FIIs/RFPIs from 40% up to an aggregate limit of 49% of the paid up share capital of the company.

Glenmark Pharmaceuticals is a research-driven, global, integrated pharmaceutical company and ranked among the top 80 Pharma & Biotech companies of the world in terms of revenues as per SCRIP 100 Rankings. Glenmark has several molecules in various stages of clinical development and primarily focused in the areas of Inflammation, Pain and Oncology. The company has significant presence in branded formulations across emerging economies including India.

Glenmark Pharma Share Price

1985.50 -15.55 (-0.78%)
28-Jan-2026 14:43 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1606.30
Dr. Reddys Lab 1221.90
Cipla 1320.00
Zydus Lifesciences 891.65
Lupin 2125.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×